10-Q: Amarin Q3 Loss Narrows, Strategic Europe Deal Drives Restructuring

Amarin Corporation plc reported a significantly reduced net loss for Q3 2025, driven by increased U.S. product revenue and strategic European partnership, despite overall nine-month revenue decline.

Summary

• Net loss for the three months ended September 30, 2025, significantly improved to $7.7 million, compared to $25.1 million for the same period in 2024.
• Total revenue for Q3 2025 increased by 17% to $49.7 million, up from $42.3 million in Q3 2024, primarily due to a $10.3 million increase in U.S. net product revenue.
• U.S. product revenue for Q3 2025 rose to $40.9 million from $30.6 million in Q3 2024, benefiting from the exit from Medicaid and 340B programs and regaining a large national pharmacy benefit manager.
• A global restructuring plan was implemented in June 2025, in connection with an exclusive long-term license and supply agreement with Recordati for VAZKEPA in 59 European countries, incurring $9.4 million in restructuring expense for Q3 2025 and $32.2 million for the nine months.
• The restructuring is expected to generate approximately $70.0 million in annual cost savings, mainly from the elimination of commercial roles in European operations.
• For the nine months ended September 30, 2025, total revenue slightly decreased by 1% to $164.4 million from $166.3 million in the prior year, primarily due to a $9.4 million decrease in U.S. product revenue over the nine-month period.
• U.S. market share for icosapent ethyl decreased to approximately 45% for the nine months ended September 30, 2025, from 55% in the prior year, largely due to a major PBM not covering VASCEPA in the first half of the year.
• Licensing and royalty revenue increased by 30% to $28.2 million for the nine months, including a $25.0 million upfront payment from the Recordati Licensing Agreement.
• Gross margin on product sales improved to 43% for Q3 2025 (from 38% in Q3 2024) and to 51% for the nine months (from 48% in the prior year), driven by a change in customer mix.
• Selling, general and administrative expenses decreased by 47% in Q3 2025 and 18% for the nine months, largely due to the Global Restructuring Plan and reduced promotional activities.
• Cash and cash equivalents, along with short-term investments, totaled $286.6 million as of September 30, 2025, with no outstanding debt.
• The company continues to support the REDUCE-IT study, with over 55 clinical treatment guidelines recognizing icosapent ethyl for CV risk reduction, including recent updates from ESC/EAS and AACE in Q3 2025.

Sentiment

Score: 7

Explanation: The significant improvement in net loss for the quarter, coupled with strong U.S. revenue growth and substantial cost savings from the European restructuring, indicates a positive strategic shift. While nine-month results show some declines due to past PBM issues and generic competition, the Q3 performance and the long-term potential of the Recordati partnership and continued clinical guideline recognition provide a favorable outlook. The company's strong liquidity and lack of debt also contribute to a positive sentiment, despite ongoing legal and market share challenges.

Positives

• Net loss significantly narrowed to $7.7 million in Q3 2025 from $25.1 million in Q3 2024, indicating improved operational efficiency and financial performance.
• Total revenue increased by 17% in Q3 2025, driven by a strong 34% increase in U.S. net product revenue to $40.9 million, attributed to strategic program exits and regaining a key PBM.
• Gross margin on product sales improved to 43% in Q3 2025 and 51% for the nine months, reflecting a favorable shift in customer mix and potentially better pricing.
• Selling, general and administrative expenses decreased substantially by 47% in Q3 2025 and 18% for the nine months, primarily due to the Global Restructuring Plan, which is expected to yield $70.0 million in annual cost savings.
• The exclusive long-term license and supply agreement with Recordati for VAZKEPA in 59 European countries provides a significant upfront payment of $25.0 million and expands market access.
• Cash used in operating activities decreased to $8.5 million for the nine months ended September 30, 2025, from $17.7 million in the prior year, indicating improved cash management.
• The company maintains a strong liquidity position with $286.6 million in cash and short-term investments and no outstanding debt as of September 30, 2025.
• Continued recognition of icosapent ethyl (IPE) in major clinical guidelines, such as the August 2025 ESC/EAS focused update and September 2025 AACE consensus statement, reinforces its clinical value and market potential.
• Regained compliance with Nasdaq's minimum bid price requirement as of April 29, 2025, mitigating immediate delisting concerns.

Negatives

• Overall total revenue for the nine months ended September 30, 2025, slightly decreased by 1% to $164.4 million, compared to $166.3 million in the prior year.
• U.S. product revenue for the nine months decreased by 8% to $113.0 million, primarily due to a large national PBM not covering VASCEPA during the first half of the year.
• U.S. market share for icosapent ethyl declined to approximately 45% for the nine months ended September 30, 2025, from 55% in the prior year, indicating increased generic competition impact.
• The company incurred significant restructuring expenses of $9.4 million in Q3 2025 and $32.2 million for the nine months, impacting short-term profitability.
• Operating loss for the nine months ended September 30, 2025, worsened to $43.8 million from $39.3 million in the prior year, and net loss also worsened to $37.6 million from $33.6 million.
• RoW product revenue, net, decreased by $3.3 million in Q3 2025 and $5.2 million for the nine months, indicating challenges in certain international markets.
• Interest income, net, decreased by 18% in Q3 2025 and 17% for the nine months, primarily due to lower interest rates.
• The company has an accumulated deficit of $1.7 billion as of September 30, 2025, reflecting historical operating losses.

Risks

• Dependence on Recordati for successful commercialization of VAZKEPA in 59 European countries, with risks including Recordati's efforts, supply chain management, pricing, personnel changes, use of intellectual property, and potential business combinations.
• The Global Restructuring Plan may not successfully mitigate business risks or establish a significant international footprint, potentially failing to achieve anticipated cost savings or market expansion.
• Inability to maintain market leadership in the U.S. due to generic competition or failure to achieve international profitability could necessitate further research and development cuts or additional funding, leading to substantial dilution or business restrictions.
• Risk of delisting from the Nasdaq Stock Market if the company fails to maintain compliance with listing requirements, such as the $1.00 minimum bid price, which could adversely impact liquidity and share price.
• Potential adverse effects on business, financial condition, results of operations, and cash flows from tariffs, trade sanctions, or similar government actions and related market volatility.
• Ongoing patent infringement lawsuit against Hikma and a lawsuit from the former CEO, Karim Mikhail, pose legal and financial uncertainties, with the company unable to reasonably estimate loss exposure for the latter.

Future Outlook

The company anticipates continued variability in quarterly net cash outflows due to the timing of API purchases and the impact of U.S. generic competition, as well as the efforts of its European licensee. Management expects to competitively manage U.S. market leadership and drive expanded access and patient uptake of VASCEPA globally through partner support and pricing/reimbursement initiatives. Research and development investment levels will be adjusted based on U.S. generic competition and global pricing reimbursements. The company believes its current liquidity will be sufficient to fund projected operations, including a potential share repurchase program, for at least one year from the financial statement issuance date.

Management Comments

• "We remain confident that the global patient need for VASCEPA is high."
• "For the remainder of 2025, we will continue to (i) competitively manage our market leadership in the U.S., and (ii) drive expanded access and increased patient uptake of VASCEPA through ongoing support of our commercialization partners and their pricing, reimbursement and licensure initiatives in non-U.S. geographies around the world."
• "We continuously evaluate all of our research and development investment commitments and priorities and are prepared to adjust such investment levels based on various factors, including the impact of U.S. generic competition, as well as timing of pricing reimbursements throughout the world."
• "We believe that our cash and cash equivalents and our short-term investments will be sufficient to fund our projected operations, including the share repurchase program if we were to decide to proceed with such, for at least one year from the issuance date of our unaudited condensed consolidated financial statements..."

Industry Context

Amarin operates in the highly competitive pharmaceutical industry, specifically targeting cardiovascular health with its product VASCEPA/VAZKEPA. The U.S. market continues to be significantly impacted by generic competition, which has eroded Amarin's market share over the nine-month period, though Q3 showed some recovery in branded prescriptions and market share. The strategic shift towards licensing in Europe with Recordati reflects a common industry trend for pharmaceutical companies to leverage partnerships for broader international market penetration while optimizing internal cost structures. The ongoing recognition of icosapent ethyl in major clinical guidelines (ESC/EAS, AACE) underscores the product's scientific validation and potential for sustained demand in the cardiovascular risk reduction segment, despite market access challenges and generic pressures.

Comparison to Industry Standards

• The U.S. icosapent ethyl market saw a 2% increase in overall prescription levels for Q3 2025 compared to Q3 2024, indicating a growing market for the drug class. Amarin's branded VASCEPA prescriptions increased by 3% in the same period, slightly outpacing the overall market growth for the quarter.
• Amarin's U.S. market share for icosapent ethyl increased to approximately 51% in Q3 2025 from 50% in Q3 2024, demonstrating a short-term gain against generic competitors like Hikma Pharmaceuticals USA Inc., Dr. Reddys Laboratories, Inc., Teva Pharmaceuticals USA, Inc., Apotex, Inc., Zydus Lifesciences, Strides Pharma, Epic Pharma, Ascent Pharmaceuticals, Inc., Qilu Pharmaceutical Co Ltd, and Spriaso LLC.
• However, for the nine months ended September 30, 2025, Amarin's U.S. market share decreased to approximately 45% from 55% in the prior year, highlighting the sustained impact of generic entry over a longer period, a common challenge for branded pharmaceuticals post-patent expiry.
• The company's strategy of licensing VAZKEPA in Europe to Recordati, a company with a strong European presence, aligns with common industry practices for maximizing market penetration in complex regulatory and reimbursement environments, similar to how other pharmaceutical companies partner for regional commercialization.
• The continued inclusion of icosapent ethyl in major clinical guidelines, such as the August 2025 ESC/EAS Guidelines and September 2025 AACE consensus statement, positions VASCEPA/VAZKEPA favorably against other lipid-modifying or cardiovascular risk reduction therapies, reinforcing its clinical utility in line with evidence-based medicine standards.

Management Changes

Legal Proceedings

• Patent infringement lawsuit against Hikma Pharmaceuticals USA Inc. for inducing infringement of patents covering VASCEPA's CV risk reduction use. The Federal Circuit reversed a prior dismissal, and Hikma's petition for rehearing was denied. Hikma filed a petition for a writ of certiorari with the U.S. Supreme Court on February 14, 2025, while the infringement case continues in district court.
• Lawsuit filed by former CEO Karim Mikhail on March 31, 2023, alleging constructive termination, breaches of employment agreement, and implied covenant of good faith and fair dealing. The case is in the U.S. District Court for the District of New Jersey, with Amarin filing a new motion to dismiss on March 20, 2025. The company believes it has valid defenses but cannot reasonably estimate the loss exposure.

Stakeholder Impact

• Shareholders: Potential for improved profitability and share value from cost savings and strategic partnerships, but also risks from generic competition and ongoing litigation. The approved share repurchase program could provide future value.
• Employees: Significant impact from the Global Restructuring Plan, which involved the elimination of commercial roles in European operations, leading to job losses.
• Customers/Patients: Continued and expanded access to VASCEPA/VAZKEPA in the U.S. and Europe through direct sales and new partnerships, supported by ongoing clinical guideline recognition.
• Suppliers: Ongoing negotiations to adjust supply agreements to align with current and future global demand, potentially impacting existing contractual obligations.
• Regulatory Authorities: Continued engagement for maintaining and expanding regulatory approvals for VASCEPA/VAZKEPA globally.

Next Steps

• Competitively manage market leadership for VASCEPA in the U.S. for the remainder of 2025.
• Drive expanded access and increased patient uptake of VASCEPA through ongoing support of commercialization partners in non-U.S. geographies.
• Continue pricing, reimbursement, and licensure initiatives with international partners.
• Continuously evaluate and adjust research and development investment levels based on U.S. generic competition and global pricing reimbursements.
• Monitor business and market conditions to potentially deploy the $50.0 million share repurchase program, approved until Q2 2029.
• Continue to negotiate with contract suppliers to align supply arrangements with current and future global market demand.
• Vigorously defend against the patent infringement lawsuit with Hikma and the lawsuit from the former CEO, Karim Mikhail.

Key Dates

Recommendation

Amarin's Q3 2025 results show significant improvement in net loss and U.S. revenue, driven by strategic adjustments and cost-cutting measures from the European restructuring. The Recordati partnership is a positive step for international market access and cost efficiency. However, the nine-month performance still reflects a decline in overall revenue and U.S. market share due to generic competition and past PBM issues. While the long-term potential of VAZKEPA is supported by clinical guidelines and European exclusivity, the company faces ongoing legal challenges and the inherent risks of relying on partners for commercialization. The stock has regained Nasdaq compliance, but maintaining it is not guaranteed. Given the mixed performance, strategic shifts, and ongoing risks, a 'hold' recommendation is appropriate, allowing investors to observe the execution of the restructuring and the performance of the new European partnership before making further commitments.

Keywords

Amarin, VASCEPA, VAZKEPA, Icosapent Ethyl, Cardiovascular Health, SEC Filing, 10-Q, Pharmaceutical, Biotech, Financial Results, Restructuring, Recordati, European Market, U.S. Market, Generic Competition, REDUCE-IT, Clinical Trials, Drug Approval, Licensing Agreement, Share Repurchase